JPS61145112A - Patch agent - Google Patents
Patch agentInfo
- Publication number
- JPS61145112A JPS61145112A JP59268125A JP26812584A JPS61145112A JP S61145112 A JPS61145112 A JP S61145112A JP 59268125 A JP59268125 A JP 59268125A JP 26812584 A JP26812584 A JP 26812584A JP S61145112 A JPS61145112 A JP S61145112A
- Authority
- JP
- Japan
- Prior art keywords
- plaster
- medicinal
- component
- blocks
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011505 plaster Substances 0.000 claims abstract description 63
- 239000004615 ingredient Substances 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract 3
- 230000003578 releasing effect Effects 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 20
- 229920006267 polyester film Polymers 0.000 description 13
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 10
- 239000003431 cross linking reagent Substances 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 239000004745 nonwoven fabric Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229960000846 camphor Drugs 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000007757 hot melt coating Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
- 229960004369 flufenamic acid Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- CPHGOBGXZQKCKI-UHFFFAOYSA-N 4,5-diphenyl-1h-imidazole Chemical compound N1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CPHGOBGXZQKCKI-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001464430 Cyanobacterium Species 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910000464 lead oxide Inorganic materials 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
本発明は貼付剤に関し、更に詳しくは２種以上の薬効成
分を含有し、膏体層が２以上に分割された貼付剤に関す
る。DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The present invention relates to a patch, and more particularly to a patch containing two or more medicinal ingredients and having a plaster layer divided into two or more.
従来の技術
従来、貼付剤の膏体は単純な混合系の単一層からなって
いた。BACKGROUND OF THE INVENTION Conventionally, plasters for adhesive patches have consisted of a single layer of a simple mixed system.
発明が解決しようとする問題点
このため、２種以上の薬効成分を膏体に含有させる場合
、薬効成分のなかには他の薬効成分まだは膏体成分と配
合することが好ましくないものも少なくないので薬効成
分の安定化が困難であり、また薬効成分の放出のコント
ロールも困難である。Problems to be Solved by the Invention For this reason, when two or more medicinal ingredients are contained in a plaster, there are many medicinal ingredients that are undesirable to be combined with other medicinal ingredients. It is difficult to stabilize the medicinal ingredients, and it is also difficult to control the release of the medicinal ingredients.
本発明者らは、これらの欠点を解消すべく鋭意研究した
結果、配合上問題がない薬効成分と膏体成分とを組にし
てプロ、り状の膏体層を形成し、このブロックを配列し
て貼付剤を形成することにより、薬効成分を安定化し、
薬効成分の放出を容易にコントロールすることに成功し
、本発明を完成した。As a result of intensive research to eliminate these drawbacks, the inventors of the present invention formed a professional adhesive-like plaster layer by combining a medicinal ingredient and a plaster component that do not have any problems in terms of formulation, and arranged these blocks. By forming a patch, the medicinal ingredients are stabilized,
The present invention was completed by successfully controlling the release of medicinal ingredients.
本発明の目的物は、２種以上の薬効成分を含有させた貼
付剤において、膏体層を２以上のブロックに分割し、前
記プ、ロックの各々に１種以上の薬効成分を含有させた
ことを特徴とする貼付剤である。The object of the present invention is a patch containing two or more types of medicinal ingredients, in which the plaster layer is divided into two or more blocks, and each of the blocks contains one or more types of medicinal ingredients. This patch is characterized by:
本発明において、薬効成分とは経皮吸収させることがで
きるか、または貼付剤に常用されている薬物であり、た
とえば、コルチコステロイド脈たとえば、グレドニゾロ
ン、酢酸グレドニゾロン。In the present invention, the medicinal ingredient is a drug that can be absorbed transdermally or is commonly used in patches, such as corticosteroids such as glednisolone and glednisolone acetate.
ヒドロコルチゾン、酢酸ヒドロコルチゾン、酪酸プロピ
オン酸ヒドロコルチゾン、ベタメタシン。Hydrocortisone, Hydrocortisone Acetate, Hydrocortisone Butyrate Propionate, Betamethacin.
青草酸ヘタメタシン、フルオシノロンアセトニド。Hetamethacin cyanobacterium, fluocinolone acetonide.
デキサメタシンなど）、麻酔剤（たとえば、ペンシカイ
ン、リドカイン、アミノ安息香酸エチルなど）、抗ヒス
タミン剤（たとえば、塩酸ジフェンヒドラミン、塩酸イ
ンサイベンジル、ジフェニールイミダゾールなど）、抗
菌剤（たとえば、塩化ベンザルコニウム、ニトロフラン
なト）、抗真菌剤（たとえば、ナイスタチン、ウンデン
レン酸。dexamethacine, etc.), anesthetics (e.g., pensicaine, lidocaine, ethyl aminobenzoate, etc.), antihistamines (e.g., diphenhydramine hydrochloride, incybenzyl hydrochloride, diphenylimidazole, etc.), antibacterial agents (e.g., benzalkonium chloride, nitrofuran, etc.). ), antifungal agents (e.g., nystatin, undenleic acid).
トルナフテートなど）、鎮痛消炎剤（たとえば、インド
メタシン、ジクロフェナックナトリウム。tolnaftate), analgesic anti-inflammatory agents (e.g., indomethacin, diclofenac sodium).
フルフェナム酸、サリチル酸ナトリウム、オウバク末、
水溶性アズレンなど）、抗生物質（たとえハ、エリスロ
マイ７ン、クロラムフェニコール。Flufenamic acid, sodium salicylate, Oubaku powder,
water-soluble azulene, etc.), antibiotics (eg, erythromycin, chloramphenicol).
セファレキシン、テトラサイクリン、ネオマシン。Cephalexin, Tetracycline, Neomacin.
ペニシリン、ペニシリンＧナトリウムＬ！：”）、貼付
剤常用薬（カンフル、メントール、泡附子、紫根、ハ、
力油、チモール、アクリノール、ロートエキス、トウガ
ラ／エキスなど）などである。これらの薬効成分のなか
には薬効成分まだは膏体成分と配合することが好ましく
ないものがある。たとえば、水溶性アズレンは、サリチ
ル酸系化合物と同一製剤中に配合すると安定領域が異な
るので、貼付剤では従来−緒に配合することができなか
った。また、酸性領域では、水溶性アズレンと紫根は不
安定であり、イノドメタンン、ジクロフエナ７クナトリ
ウム、フルフェナム酸などは析出する。Penicillin, penicillin G sodium L! :”), common medicines for patches (camphor, menthol, foam, purple root, ha,
oil, thymol, acrinol, funnel extract, chili pepper/extract, etc.). Some of these medicinal ingredients are not yet suitable for combination with plaster components. For example, water-soluble azulene and salicylic acid compounds have different stability ranges when combined in the same formulation, so conventionally they could not be combined together in a patch. Further, in an acidic region, water-soluble azulene and purple root are unstable, and inodomethane, diclofenac sodium, flufenamic acid, etc. precipitate.
アルカリ性領域ではサリチル酸エステル類は不安定であ
る。ペニシリンＧナトリウムはグリセリンで分解をおこ
し、サリチル酸す） ＩＪウムは炭酸水素ナトリウムで
変色をおこし、オウバク末はカオリンで変色をおこす。Salicylates are unstable in alkaline regions. (Sodium penicillin G is decomposed with glycerin and then salicylic acid is added.) IJium is discolored with sodium bicarbonate, and Aurubaku powder is discolored with kaolin.
膏体層は各膏体、７゛口、りを接続させて連続層を形成
させることができるし、また各膏体プロ、りを離隔して
不連続層を形成することもできる。The plaster layer can be formed by connecting the respective plaster layers to form a continuous layer, or by separating the plaster layers from each other to form a discontinuous layer.
連続膏体層には、たとえば第１図に示すような異種の縦
紬ブロックを交互に接続配列したストライプタイプや第
２図に示すような、ある種の膏体層中に異種の小ブロッ
クを散在させたスポットタイプなどがある。Continuous plaster layers include, for example, a stripe type in which vertical pongee blocks of different types are alternately connected and arranged as shown in Figure 1, or a type of continuous plaster layer in which small blocks of different types are arranged in a certain type of plaster layer as shown in Figure 2. There are scattered spot types.
連続膏体層においては、相隣るプロ、りは相互に親和性
のない膏体（たとえば、親水性の膏体と親油性の膏体な
ど）からなる。この場合の膏体は、配合する薬効成分と
配合上問題がない成分からなる。In a continuous plaster layer, adjacent layers are composed of plasters that have no affinity with each other (for example, a hydrophilic plaster and a lipophilic plaster). In this case, the paste consists of medicinal ingredients and ingredients that are compatible with the formulation.
たとえば、親水性膏体は次の方法によシ調製することが
できる。For example, a hydrophilic plaster can be prepared by the following method.
まず、軽質流動パラフィン〔たとえば、ハイコールに−
２３０（商品名、金山油化■）〕１５〜２０部、インブ
レンゴム〔たとえば、グラプレン（商品名、フラン■）
〕１〜５部およびスチレン−イソプレン−スチレンテレ
プロ、り共重合ゴム〔たとえば、カリフレ、クス ＤＥ
−１１２，Ｓ工５ＴＲ１１０７（いずれも商品名、シェ
ル化学■）など〕１〜５部を混合溶解し、これをカルボ
キシ変性液状ポリイソプレンゴム〔粘度平均分子量１０
、０００〜９０．０００、望ましくは２０．０００〜５
０，０００．１分子当りのカルボキン基数３〜２０、望
ましくは１０程のもの。たとえばクラプレンＬ工Ｒ（商
品名、フランイノプレンケミカル■）〕１２〜１８部に
溶解する。これに非イオン界面活性剤〔たとえば、二、
コールＭａｓ−Ｂｓｚ−ｃ（商品名２日光ケミカルズ■
） ） Ｏ，Ｓ〜４部と金属石鹸〔たとえば、ステアリ
ン酸マグネンウム〕１〜５部を加えて攪拌した後、精製
水３０〜５０部と親水性薬効成分（たとえば、水溶性ア
ズレン、インドメタシンなど）所要量を徐々に滴下しな
がら乳化、分散し、エマルジョンを生成する。First, light liquid paraffin [for example, Hycoal-
230 (trade name, Kanayama Yuka ■)] 15-20 parts, Inbrene rubber [for example, Graprene (trade name, Furan ■)]
] 1 to 5 parts and styrene-isoprene-styrene telepropolymer rubber [e.g., Carifre, Kusu DE
-112, S-5TR1107 (both trade names, Shell Chemical ■), etc.] were mixed and dissolved, and this was mixed and dissolved with carboxy-modified liquid polyisoprene rubber [viscosity average molecular weight 10
,000-90.000, preferably 20.000-5
0,000.The number of carboxyne groups per molecule is 3 to 20, preferably about 10. For example, it is dissolved in 12 to 18 parts of Kraprene L-KR (trade name, Furinoprene Chemical ■). This is combined with a nonionic surfactant [e.g.
Coal Mas-Bsz-c (Product name 2 Nikko Chemicals■
) ) ~4 parts of O, S and 1 to 5 parts of metal soap [e.g., magnenium stearate] are added and stirred, followed by 30 to 50 parts of purified water and a hydrophilic medicinal ingredient (e.g., water-soluble azulene, indomethacin, etc.). Gradually drop the required amount to emulsify and disperse to form an emulsion.
別に賦型剤（たとえば、カオリ／、べ／トナイト、酸化
チタン、酸化亜鉛、炭酸カルシウム、メタケイ酸アルミ
ン酸マダイ・シウムなど）７〜１５部および架橋剤（た
とえば、金属系架橋剤、アミン系架橋剤、エポキン系架
橋剤、グリコール系架橋剤、インシアネート系架橋剤な
ど、好ましくは酸化鉛、酸化マグネシウム、水酸化カル
ノウムなどの金属系架橋剤）０．５〜５部を均一に混合
しておき、これを前記エマルジョンに加えて７０〜９０
℃で分散した後、貼付剤常用薬〔たとえば、メノト−／
ｌ／、 カンフ ／ｌ／、 ハツカ油、チモール、
トウカラ／エキスなど、好ましくはメントール−カンフ
ル１．１（重量比）共溶融液など〕０５〜２部を滴下、
混合して親水性膏体を得る。Separately, 7 to 15 parts of excipients (e.g., kaori, betonite, titanium oxide, zinc oxide, calcium carbonate, red sea bream aluminate metasilicate, etc.) and a crosslinking agent (e.g., metal crosslinking agent, amine crosslinking agent, etc.) 0.5 to 5 parts of a crosslinking agent, Epoquine crosslinking agent, glycol crosslinking agent, incyanate crosslinking agent, etc., preferably a metal crosslinking agent such as lead oxide, magnesium oxide, carnoum hydroxide, etc.) are mixed uniformly. , add this to the emulsion and add 70 to 90
After dispersion at
l/, camphu /l/, peppermint oil, thymol,
Drop 05 to 2 parts of toucara/extract, preferably menthol-camphor 1.1 (weight ratio) co-melt solution, etc.
Mix to obtain a hydrophilic paste.
まだ、たとえば親油性膏体は次の方法により調製するこ
とができる。Still, for example, lipophilic plasters can be prepared by the following method.
スチレン−イソプレン−スチレンテレプロ、り共重合ゴ
ム２０〜２６部に流動パラフィン１２〜１６部を含浸さ
せ、これに脂環族飽和炭化水素樹脂〔テルペン系樹脂、
ロジン系樹脂などの粘着性付与樹脂。たとえば、アルコ
ンＰ−８５（商品名。20 to 26 parts of styrene-isoprene-styrene telepropolymer rubber is impregnated with 12 to 16 parts of liquid paraffin, and this is impregnated with alicyclic saturated hydrocarbon resin [terpene resin,
Tackifying resins such as rosin resins. For example, Alcon P-85 (trade name).
部用化学■）〕４０〜４５部および賦型剤６〜１２部を
加えて混練する。これに親油性薬効成分（たとえば、サ
リチル酸メチル、酪酸プロピオン酸ヒドロコルチゾンな
ど）所要量と貼付剤常用薬８〜１４部の共溶融液を添加
、混合して親油性膏体を得る。Add 40 to 45 parts of Department Chemical ■) and 6 to 12 parts of excipient and knead. A co-melt solution of a required amount of a lipophilic medicinal ingredient (for example, methyl salicylate, hydrocortisone butyrate propionate, etc.) and 8 to 14 parts of a commonly used patch is added and mixed to obtain a lipophilic paste.
このようにして調製した相互に親和性のない膏体Ａ、
Ｂを用いて、たとえば次の方法によυ本発明の貼付剤
を調製する。Mutually incompatible plaster A prepared in this way,
Using B, the patch of the present invention is prepared, for example, by the following method.
すなわち、膏体Ａをポンプでホットメルトコーティング
・アプリケーターに送り、剥離片（たとえば、片面をシ
リコン処理したポリエステルフィルム）にストライプ状
またはスポット状に膏体フロ、りを形成する。That is, the paste A is sent to a hot melt coating applicator by a pump, and the paste is formed in stripes or spots on a peelable piece (for example, a polyester film treated with silicone on one side).
また、膏体Ｂをポンプで別のホットメルトコーティング
・アプリケーターだ送り、支持体（たとえば、不織布、
綿布など）上の、剥離片の膏体空隙部に対応する位置に
その空隙部と一致する膏体ブロックを形成する。In addition, the paste B is pumped to another hot melt coating applicator and the support (e.g., non-woven fabric,
A plaster block is formed on a cotton cloth, etc.) at a position corresponding to the plaster cavity of the peelable piece and matches the cavity.
このようＫして調製した膏体Ａ塗着剥離片と膏体Ｂ塗着
支持体を重ね合せ、２本のローラーの間を通して圧着し
、連続膏体層を形成してストライブタイプまたはスポッ
トタイプの本発明の貼付剤を得ることができる。The peelable piece coated with plaster A and the support coated with plaster B prepared in this way are superimposed and pressed between two rollers to form a continuous plaster layer, resulting in a stripe type or spot type. The patch of the present invention can be obtained.
また、同様にして膏体Ａを剥離片上に膏体ブロックを形
成し、支持体上の、剥離片の空隙部に対応 １
′する位置にその空隙部より小さな膏体プロ、りを形成
した後、膏体Ａ塗着剥離片と膏体Ｂ塗着支持体を合せ、
２本のローラーの間を通して圧着し、不連続膏体層を有
する本発明の貼付剤を得ることができる。In addition, in the same manner, a plaster block was formed on the peelable piece using plaster A, and the plaster block was formed to correspond to the gap of the peelable piece on the support.
After forming a paste smaller than the gap at the position where the paste is to be applied, the paste A-applied peeling piece and the plaster B-applied support are put together,
The patch of the present invention having a discontinuous plaster layer can be obtained by pressing between two rollers.
必要があれば各膏体に着色材料を加えて各ブロックを着
色することもできる。If necessary, each block can be colored by adding a coloring material to each plaster.
作 用
本発明においては、打撲、炎症、皮膚疾患などの患部の
治療に必要な２以上の薬効成分を配合上問題がないグル
ープに区分し、各グループの薬効成分と、これと配合上
問題がなくて放出性がよい膏体成分を用いて相隣る膏体
プロ、りと親和性のない膏体プロ、りを支持体上に形成
する。膏体プロ、りは連続する膏体層においても相隣る
膏体層と親和性がないので、各膏体ブロックに配合され
た薬効成分は隣接する膏体プロ、りに移行することなく
患部方向にのみ移行する。Function: In the present invention, two or more medicinal ingredients necessary for treating affected areas such as bruises, inflammation, and skin diseases are divided into groups that do not cause any problems in combination, and the medicinal ingredients in each group and those in which there are problems in combination are classified. A paste component that has good releasability without any affinity is used to form a paste component on a support that has no affinity with adjacent plaster components. Even in consecutive plaster layers, the plaster blocks have no affinity with adjacent plaster layers, so the medicinal ingredients contained in each plaster block can be transferred to the affected area without transferring to the adjacent plaster blocks. Migrate only in the direction.
非連続の膏体層においても、各膏体ブロック間には空隙
があるので、各膏体プロ、りに配合された薬効成分は隣
の膏体ブロックに移行することなく患部方向にのみ移行
する。Even in a discontinuous plaster layer, there are gaps between each plaster block, so the medicinal ingredients contained in each plaster block will only migrate towards the affected area without transferring to the adjacent plaster block. .
発明の効果
従って、本発明の貼付剤は、配合上の制約を受けること
なく治療に必要な薬効成分を配合することができて薬効
成分の放出性がよいので、治療効果を著しく向上するこ
とができる。Effects of the Invention Therefore, the patch of the present invention can contain the medicinal ingredients necessary for treatment without being subject to formulation restrictions, and has good release properties of the medicinal ingredients, so it can significantly improve the therapeutic effect. can.
まだ、各膏体プロ、りを着色することによって膏体面が
美しい貼付剤を得ることもできる。However, it is also possible to obtain a patch with a beautiful plaster surface by coloring each adhesive.
実施例
実施例 １
（１）ハイコールに−２５０１８部にロジンプレンＩＲ
−１０３部とカリフレ、クスＤＥ−１１２３部を混合、
溶解し、これにクラプレンＬ工Ｒ′〔粘度（３８℃）
１８００ポイズ、１分子当りのカルボキシル基数 約
１０〕１５部を加えて均一に溶解し、油性の連続相を形
成した。Examples Example 1 (1) -25018 parts of Rosinprene IR in Hykol
-103 parts and Caulifu, Kusu DE-1123 parts mixed,
Dissolve and add Kraprene L-R' [viscosity (38℃)
15 parts (1800 poise, number of carboxyl groups per molecule: approximately 10) were added and uniformly dissolved to form an oily continuous phase.
室温で攪拌しながら、これにニラコールＭＧＳ−ＢＳＥ
−１１： １部とステアリン酸マグネ７ウム ３部を
加え、更にこれに精製水４０部と水溶性アズレン１部を
徐々に滴下しながら油性の連続相に乳化９分散し、エマ
ルジョンを形成した。While stirring at room temperature, add Niracol MGS-BSE to this.
-11: 1 part and 3 parts of magnesium stearate were added, and 40 parts of purified water and 1 part of water-soluble azulene were gradually added dropwise to emulsify and disperse in the oily continuous phase to form an emulsion.
別にカオリン８部、酸化チタン１部、酸化マグネシウム
１部を混合機で均一に分散し、これを前記のエマルジョ
ンに加え、８０℃で約３０分間混合し、均一にした。こ
れに更にメントール−カンフル１：１（重量比）共溶融
液１部を滴下、混合して親水性膏体を調製した。Separately, 8 parts of kaolin, 1 part of titanium oxide, and 1 part of magnesium oxide were uniformly dispersed in a mixer, added to the emulsion, and mixed at 80° C. for about 30 minutes to make the mixture uniform. Further, 1 part of a menthol-camphor 1:1 (weight ratio) co-melt solution was added dropwise and mixed to prepare a hydrophilic paste.
（２）Ｓ工Ｓ ＴＲ１１０７２３，３部にハイコール
に−２３０１４部を含浸させ、９０〜１１０℃でこれに
アルコンＰ−８５４３部、酸化チタン２部、メタケイ酸
アルミン酸マグネシウム１．５部、炭酸カルシウム５部
を加えて混練し、均一にした。(2) 3 parts of S Engineering S TR110723 is impregnated with -23014 parts of Hycol, and added to this at 90 to 110°C, 3 parts of Alcon P-8543, 2 parts of titanium oxide, 1.5 parts of magnesium aluminate metasilicate, and calcium carbonate. 5 parts were added and kneaded until uniform.
次に、サリチル酸メチル２６部、カンフル２．６部、メ
ントール７５部からなる共溶融液をこれに添加、混合し
て親油性膏体を調製した。Next, a co-melt solution consisting of 26 parts of methyl salicylate, 2.6 parts of camphor, and 75 parts of menthol was added and mixed to prepare a lipophilic paste.
（３）前項（１）で調製した親水性膏体をポンプでホッ
トメルトコーティング・アプリケーターに送り、片面に
シリコン処理を施してロール状に巻いたポリエステルフ
ィルムの一端をひっばって不織布との重ね合せ位置に導
きながら、そのシリコン処理面にストライプ状の膏体プ
ロ、りを形成していった。(3) The hydrophilic paste prepared in the previous section (1) is sent to a hot melt coating applicator using a pump, one side of the polyester film is treated with silicone, and one end of the rolled polyester film is stretched and overlaid with a nonwoven fabric. While guiding it to the desired position, a striped paste was formed on the silicone-treated surface.
また、前項（２）で調製した親油性膏体をポンプで別の
ホットメルトコーティング・アプリケーターに送り、ロ
ール状に巻いた不織布（日本パイＩＪ−ン■製）の一端
をひっばってポリエステルフィルムとの重ね合せ位置に
導きながら、その表面の、前記ポリエステルフィルムの
膏体空隙部に対応ず部
る位置にその空懸（一致する膏体プロ、りを形成してい
った。In addition, the lipophilic paste prepared in the previous section (2) was pumped to another hot melt coating applicator, and one end of the rolled nonwoven fabric (manufactured by Nippon Pai IJ-N) was stretched to form a polyester film. While guiding the polyester film to the overlapping position, a gap was formed on the surface of the polyester film at a position that did not correspond to the gap in the plaster.
このようにして調製した膏体プロ、り形成ポリエステル
フィルムと膏体ブロック形成不織布を重ね合せ、２本の
ローラーの間を通して圧着し、連続膏体層を形成した後
、適当なサイズに切断してストライプタイプの本発明の
貼付剤を得た。The plaster block-forming polyester film and the plaster block-forming nonwoven fabric prepared in this way were layered and pressed between two rollers to form a continuous plaster layer, and then cut into appropriate sizes. A stripe-type adhesive patch of the present invention was obtained.
実施例 ２
実施例１で使用のポリエステルフィルムのシリコン処理
面に実施例１（１）で調製の親水性膏体でスポット状の
膏体ブロックを形成、配列し、実施例１で使用の不織布
に、実施例１（２）で調製の親油性膏体で、前記ポリエ
ステルフィルムに形成したスポット状膏体ブロックに対
応する部分を空隙部とした穴あき状膏体プロ、りを形成
するほかは実施例１に準じて、スポットタイプの本発明
の貼付剤を得た。Example 2 Spot-shaped plaster blocks were formed and arranged on the silicone-treated surface of the polyester film used in Example 1 using the hydrophilic plaster prepared in Example 1 (1), and then placed on the nonwoven fabric used in Example 1. The same procedure was carried out except that a perforated plaster was formed using the lipophilic plaster prepared in Example 1 (2), with the portions corresponding to the spot-shaped plaster blocks formed on the polyester film as voids. According to Example 1, a spot type patch of the present invention was obtained.
実施例 ３
実施例１で使用のポリエステルフィルムのシリコン処理
面に実施例１０）で調製の親水性膏体で長方形状の膏体
プロ、りを形成、配列し、実施例１で使用の不織布に、
実施例１（２）で調製の親油性膏体で、前記ポリエステ
ルフィルムに形成した長方形状膏体ブロックと重ならな
い部分にその膏体ブロックとの間に間隔が生ずるように
長方形状膏体ブロックを形成するほかは実施例１に準じ
て、２種の長方形状膏体ブロックが間隔を置いて配列さ
れた不連続膏体層の本発明の貼付剤を得だ。Example 3 A rectangular adhesive was formed and arranged on the silicone-treated surface of the polyester film used in Example 1 using the hydrophilic adhesive prepared in Example 10), and a rectangular adhesive was formed and arranged on the silicone-treated surface of the polyester film used in Example 1. ,
Using the lipophilic plaster prepared in Example 1 (2), a rectangular plaster block was formed on the polyester film so that a gap was created between the rectangular plaster block and the part that did not overlap with the rectangular plaster block formed on the polyester film. A patch of the present invention having a discontinuous plaster layer in which two types of rectangular plaster blocks were arranged at intervals was obtained in accordance with Example 1 except for the formation.
第１図は、剥離片を一部剥離した、ストライプタイプの
本発明の貼付剤の斜視図である。
第２図は、剥離片を一部剥離した、スポットタイプの本
発明の貼付剤の斜視図である。
各図において、１は剥離片、２は支持体、５および４は
相互に親和性がない膏体ブロックを示す。FIG. 1 is a perspective view of a stripe-type adhesive patch of the present invention with a peelable piece partially peeled off. FIG. 2 is a perspective view of a spot type patch of the present invention with a part of the peelable piece peeled off. In each figure, 1 is a peelable piece, 2 is a support, and 5 and 4 are plaster blocks that are not compatible with each other.
Claims (1)
膏体層を２以上のブロックに分割し、前記ブロックの各
々に１種以上の薬効成分を含有させたことを特徴とする
貼付剤。1) In a patch containing two or more medicinal ingredients,
A patch characterized in that the plaster layer is divided into two or more blocks, and each of the blocks contains one or more medicinal ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59268125A JPH0611698B2 (en) | 1984-12-19 | 1984-12-19 | Patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59268125A JPH0611698B2 (en) | 1984-12-19 | 1984-12-19 | Patch |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61145112A true JPS61145112A (en) | 1986-07-02 |
| JPH0611698B2 JPH0611698B2 (en) | 1994-02-16 |
Family
ID=17454228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59268125A Expired - Lifetime JPH0611698B2 (en) | 1984-12-19 | 1984-12-19 | Patch |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0611698B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61267510A (en) * | 1985-05-20 | 1986-11-27 | Nitto Electric Ind Co Ltd | Medicinal material for external use |
| JPS63141923A (en) * | 1986-12-04 | 1988-06-14 | Taisho Pharmaceut Co Ltd | Production of application agent |
| KR100602434B1 (en) | 2004-09-10 | 2006-07-19 | 최상식 | A patch for the transdermal administration of drugs containing a plurality of unit compartments |
| JP2012092127A (en) * | 2003-08-20 | 2012-05-17 | Lts Lohmann Therapie-Systeme Ag | Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease |
| JP2012193137A (en) * | 2011-03-15 | 2012-10-11 | Lintec Corp | Transdermal absorption type additive agent |
| JP2012201612A (en) * | 2011-03-24 | 2012-10-22 | Lintec Corp | Percutaneous absorption type adhesive skin patch agent kit |
| JP2013231021A (en) * | 2012-05-01 | 2013-11-14 | Jem International Inc | Plaster |
| JP2016141675A (en) * | 2015-02-05 | 2016-08-08 | 久光製薬株式会社 | Patches |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5699410A (en) * | 1980-01-10 | 1981-08-10 | Japan Vilene Co Ltd | Plaster |
| JPS5721316A (en) * | 1980-07-14 | 1982-02-04 | Nitto Electric Ind Co Ltd | Plaster |
| JPS5826888A (en) * | 1981-07-31 | 1983-02-17 | スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ | Beta-glycosyl c-nucleoside compound |
-
1984
- 1984-12-19 JP JP59268125A patent/JPH0611698B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5699410A (en) * | 1980-01-10 | 1981-08-10 | Japan Vilene Co Ltd | Plaster |
| JPS5721316A (en) * | 1980-07-14 | 1982-02-04 | Nitto Electric Ind Co Ltd | Plaster |
| JPS5826888A (en) * | 1981-07-31 | 1983-02-17 | スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ | Beta-glycosyl c-nucleoside compound |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61267510A (en) * | 1985-05-20 | 1986-11-27 | Nitto Electric Ind Co Ltd | Medicinal material for external use |
| JPS63141923A (en) * | 1986-12-04 | 1988-06-14 | Taisho Pharmaceut Co Ltd | Production of application agent |
| JPH0816053B2 (en) * | 1986-12-04 | 1996-02-21 | 大正製薬株式会社 | Method of manufacturing patch |
| JP2012092127A (en) * | 2003-08-20 | 2012-05-17 | Lts Lohmann Therapie-Systeme Ag | Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease |
| US8980308B2 (en) | 2003-08-20 | 2015-03-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal pharmaceutical preparation containing active substance combinations, for treating Parkinson's disease |
| KR100602434B1 (en) | 2004-09-10 | 2006-07-19 | 최상식 | A patch for the transdermal administration of drugs containing a plurality of unit compartments |
| JP2012193137A (en) * | 2011-03-15 | 2012-10-11 | Lintec Corp | Transdermal absorption type additive agent |
| JP2012201612A (en) * | 2011-03-24 | 2012-10-22 | Lintec Corp | Percutaneous absorption type adhesive skin patch agent kit |
| JP2013231021A (en) * | 2012-05-01 | 2013-11-14 | Jem International Inc | Plaster |
| JP2016141675A (en) * | 2015-02-05 | 2016-08-08 | 久光製薬株式会社 | Patches |
| WO2016125878A1 (en) * | 2015-02-05 | 2016-08-11 | 久光製薬株式会社 | Adhesive patch |
| US10292941B2 (en) | 2015-02-05 | 2019-05-21 | Hitsamitsu Pharmaceutical Co., Inc. | Adhesive patch |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0611698B2 (en) | 1994-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT395815B (en) | THERAPEUTIC DELIVERY SYSTEM FOR THE ADMINISTRATION OF AN ACTIVE SUBSTANCE THROUGH THE SKIN | |
| CA2377301C (en) | Controlled release and taste masking oral pharmaceutical compositions | |
| AU621034B2 (en) | Transdermal fertility control system | |
| KR101154327B1 (en) | manufacturing method of hydrogel patch for wound-healing | |
| JPS6214526B2 (en) | ||
| JPH10500117A (en) | Hydrophilic pressure-sensitive hot melt adhesive | |
| WO2006090782A1 (en) | Composition for hydrous adhesive patch for external use and adhesive patch comprising the composition | |
| JPH0791397B2 (en) | Flexible hydrophilic gel film, and method of making and using the same | |
| WO2004047820A1 (en) | Warm poultice | |
| JP3739100B2 (en) | Low temperature crosslinking gel | |
| JPS61145112A (en) | Patch agent | |
| US5296230A (en) | Transdermal fertility control system and process | |
| JP3032299B2 (en) | Pridinol-containing patch | |
| KR100215278B1 (en) | Plaster preparation | |
| EP0144486A2 (en) | Controlled-release drugsystem and process for preparing it | |
| JPS5936608A (en) | Novel application drug | |
| JPS63145222A (en) | Cataplasm | |
| JP4575632B2 (en) | Drugs for migraine relief | |
| JPS63141923A (en) | Production of application agent | |
| JPS61268631A (en) | Dermal external drug having improved percutaneous absorbability | |
| JPH09315964A (en) | Cataplasm for stiff shoulder and frozen shoulder syndrome | |
| JPH0853354A (en) | Aqueous plaster for dermatosis | |
| JP3496169B2 (en) | Plaster and production method thereof | |
| JPS61122211A (en) | Gradually releasing adhesive for oral mucosa | |
| JP2692127B2 (en) | Method for producing striped patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |